Clinical Trial Search

Primary: Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS) — 24.5 percentage of participants

Primary: ADAS-cog Change From Baseline to Week 52 — 7.08; 7.45; 7.91 units on a scale — p=0.3919

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 40.0; 60.0; 100.0 percentage of participants

Primary: Phase I Maximum Tolerated Dose of Nab-Paclitaxel — 20 mg/m^2

Primary: Frequency of Influenza-specific Cluster of Differentiation 4+ (CD4+) T-cells Expressing at Least 2 Markers — 3229.25; 1646.05; 3056.06; 2589.31 T-cells/million cells

Primary: Time to Disease Progression — 25.8; 29.2; 25.8 Months

Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients

Primary: Hazard of Progression in the Placebo/Placebo Arm and the Pooled Demcizumab Arms — 38; 70; 5; 12 Participants — p==0.7158

Primary: TSH Response to TRH — 11.47 mcIU/mL

Primary: Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit — 0.834; 0.775 nmol/L — p=0.048

Primary: Phase I: Maximum Tolerated Dose (MTD) of Lenalidomide — 10 milligrams

Primary: Glycemic Response During Exercise and Early Recovery — 86; 85; 174; 161 mg/dL — p=<0.001

Primary: The Primary Objective of the Trial is to Assess the Efficacy of the Combined Use of Valproic Acid (VPA) in Combination With 5-Azacytidine (5-Aza C) in the Treatment of…

Primary: Overall Nighttime Driving Score — -0.308; -0.375; -0.430 Z-Score

Primary: Treatment-Related Mortality (TRM) Defined as Non Relapse Mortality (NRM) — 10 percentage of participants